Research area · week to 3 Oct 2026

Prostate Cancer Treatment and Research

Moving in Cancer Discovery, New England Journal of Medicine.

Moved this week: 2

Rebuilt 3 October 2026 at 3:19 pm AEST

Moved this week

Everything that moved →

PROTEUS May Mean New SOC for Some Prostate Cancers.
Cancer Discovery · 9 June 2026 · News
Adding apalutamide to androgen deprivation therapy improves 5-year metastasis-free survival to 78.2% in high-risk localized prostate cancer patients.
- In the news
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42261650
Open in JClub
Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
New England Journal of Medicine · 6 Aug 2026 · Randomized Controlled Trial
Perioperative ADT plus apalutamide improves pathological response and metastasis-free survival in high-risk prostate cancer patients undergoing prostatectomy, with 8.9% achieving complete response.
- 26 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42223077
Open in JClub

Latest in Prostate Cancer Treatment and Research

Newest first · last 60 days

Disruption of NUAK2-Mediated RNA Splicing by Trilaciclib Reveals a Therapeutic Vulnerability in AR-Indifferent Prostate Cancer
bioRxiv · 25 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.11.12.687734
Open in JClub
Identification and Characterization of PCAHIT, a Novel Long Non-Coding RNA Associated with Poor Outcomes in Prostate Cancer
bioRxiv · 10 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.05.21.655369
Open in JClub
Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.
Nature Communications · 9 Sept 2026 · Journal Article
Biallelic epigenetic inactivation of ZFHX3 occurs at a recurrence rate comparable to TP53 in prostate cancer, promoting oncogene upregulation and metastasis.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42716948
Open in JClub
The benefits, harms, and cost-effectiveness of age-based and risk-stratified screening for prostate cancer with MRI
medRxiv · 9 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2025.11.28.25341221
Open in JClub
Mass Spectrometry-Based Profiling of Deuterium-Labeled Sex Steroids Enables Non-Invasive Mapping of Steroid Dynamics in Intact Mice
bioRxiv · 9 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2025.12.16.694587
Open in JClub
Integrated signatures define mutational processes in prostate cancer.
Nature · 9 Sept 2026 · Journal Article
Integrated mutational signatures in prostate cancer reveal eight key footprints explaining 85% of genomes and link to clinical outcomes.
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42717097
Open in JClub
DNA damage repair gene defects combined predict the efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: a retrospective cohort study.
Frontiers in Genetics · 1 Sept 2026 · Journal Article
Combined DDR gene mutation profiling with TMB and PD-L1 predicts immunotherapy response in 152 metastatic castration-resistant prostate cancer patients, with an AUC of 0.83.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42741774
Open in JClub
Hepatic steatosis as an architect of CRC metastatic niche.
Journal of hepatology · 25 Aug 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42642312
Open in JClub
Extracellular matrix regulates lineage plasticity in prostate cancer through YAP/TEAD
bioRxiv · 23 Aug 2026 · Preprint
Disruption of extracellular matrix-integrin-YAP/TEAD signaling triggers neuroendocrine lineage transition in prostate cancer, with significant implications for therapy resistance.
- Open access
- 3 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2025.12.30.697072
Open in JClub
Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival
bioRxiv · 18 Aug 2026 · Preprint
Read the brief in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.04.27.650697
Open in JClub
Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
New England Journal of Medicine · 6 Aug 2026 · Randomized Controlled Trial
Perioperative ADT plus apalutamide improves pathological response and metastasis-free survival in high-risk prostate cancer patients undergoing prostatectomy, with 8.9% achieving complete response.
- 26 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42223077
Open in JClub

Follow this area in the app

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read

Moved this week

Latest in Prostate Cancer Treatment and Research

Browse JClub